Team

EMD photo

Eve Damiano

Clinical Operations and Regulatory Compliance

Eve Damiano, MS, RAC, has over 30 years of professional experience in the Biotechnology Sector, specializing in regulatory affairs and GxP compliance.  Ms. Damiano has garnered depth of expertise from discovery through post-marketing activities, including various therapeutic areas.  She has served in senior management positions at multiple companies, and in a broad range of therapeutic areas.  Ms. Damiano has prepared numerous applications to support investigation and marketing of FDA regulated products. She holds an accomplished track record in the definition and execution of development/regulatory strategies, including innovative solutions and effective management of projects and resources to meet company objectives.  Ms. Damiano earned her BS degree from California University of Pennsylvania and MS degree from The Drexel College of Medicine, and has been a Regulatory Affairs Certified (RAC) professional since 2006.

Rohinton LinkedIn

Rohinton Terapore, Ph.D.

Associate Director, Clinical Research

As the Research & Development Associate, Rohinton manages the non-clinical studies and clinical trials, and drafts reports and communication material targeted for the FDA.  Dr. Tarapore received his PhD. from the University of Wisconsin – Madison and did his postdoctoral training at the University of Pennsylvania Medical School. While at Penn, he was co-chair of the Biomedical Postdoctoral Council, conceptualized the idea of hosting vendor shows & raised $65,000 for postdoctoral-related activities, and drafted several policies for enhancing the post-doctoral training at the institution. Dr. Tarapore has authored several research publications in cancer signaling, small molecules, inflammation, diabetes and toxicology and has a deep knowledge on signaling pathways that are de-regulated in oncology. Dr. Tarapore joined Oncoceutics at the beginning of 2015.

Bryce Istvan

Bryce Istvan, CFA

Associate – Finance and Business Development

As the Associate for finance and business development, Bryce is responsible for the day-to-day financial operations of the company, including accounting, financial reporting, and grant management, and supports senior management with investor relations, public relations and business development. He joins Oncoceutics having most recently been an Analyst at Osage University Partners, a Philadelphia-area venture capital firm focused on investing in university spinout companies. Previously he worked at the University City Science Center supporting a proof-of-concept grant program for commercialization of academic research, and at BlackRock where he was responsible for money market and municipal bond fund operations. He is a graduate of Drexel University, with a B.S. in Finance and Entrepreneurship and a minor in Biological Sciences.

Varun

Varun Prabhu, Ph.D.

Associate Director, Research and Development

As the Associate Research Scientist, Varun is responsible for supporting preclinical activities, as well as pursuing opportunities for grants and research collaborations. He has worked collaboratively with Oncoceutics since 2012, as a researcher in the lab of scientific founder Dr. Wafik El-Deiry, on the mechanism of action, biomarkers and combinatorial efficacy of ONC201. Dr. Prabhu was the first to demonstrate the anti-cancer stem cell efficacy of ONC201. He has co-authored several peer-reviewed publications exploring cancer therapeutics targeting apoptosis pathways, tumor suppressor genes and stem cell self-renewal. He completed his B.S. in Pharmaceutical Sciences from the Institute of Chemical Technology in India, received a M.S. in Biotechnology from the University at Buffalo, SUNY and earned a Ph.D. in Molecular Medicine from Pennsylvania State University. He has previously held research positions at the Roswell Park Cancer Institute, the Fox Chase Cancer Center and OncoMed Pharmaceuticals. Dr. Prabhu has received several awards including the Penn State Alumni Association Dissertation Award and an Innovation Award from MedImmune.